Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation

Uterine leiomyosarcoma (uLMS) is an aggressive mesenchymal tumor associated with a poor prognosis. Research demonstrates that PARP inhibitors (PARPi) improve disease-stable survival in patients with somatic BRCA1/2 mutations through the process of synthetic lethality. Therefore, PARPi’s may have a r...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Natalie Shammas, Tiffany Yang, Alireza Abidi, Malaika Amneus, Melissa Hodeib
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2022-08-01
Cyfres:	Gynecologic Oncology Reports
Pynciau:	PARP inhibitor Leiomyosarcoma Soft tissue sarcoma Uterine
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S2352578922001242
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!